Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 3069-3076

  Melichar, Bohuslav ^a,b   Ferrandina, Gabriella ^a,c   Verschraegen, Claire F ^a   Loercher, Amy ^a   Abbruzzese, James L ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; KYNURENINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEVINOLIN; PHENYLACETIC ACID;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG DETERMINATION; DRUG POTENCY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

AMINOBUTYRIC ACIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION MOLECULES; CELL DIVISION; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY ACIDS; FEMALE; HLA ANTIGENS; HUMANS; KYNURENINE; LOVASTATIN; MEVALONIC ACID; OVARIAN NEOPLASMS; PACLITAXEL; PHENYLACETATES; TRANSFORMING GROWTH FACTORS; TUMOR CELLS, CULTURED;

EID: 0032420785     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Samid, D., Shack, S., and Sherman, L. T. Phenylacetate. A novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
2. Samid, D., Shack, S., and Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91: 2288-2295, 1993.
3. Ferrandina, G., Melichar, B., Loercher, A., Verschraegen, C., Kudelka, A. P., Edwards, C. L., Scambia, G., Kavanagh, J. J., Abbruzzese, J. L., and Freedman, R. S. Growth inhibitory effects of sodium-phenylacetate (NSC #3039) on ovarian carcinoma cells in vitro. Cancer Res., 57: 4309-4315, 1997.
4. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, A. O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D., and Myers, C. E. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
5. Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N., Headlee, D. U., Kohler, D. R., Venzon, D. J., and Myers, C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2932-2938, 1995.
6. Liu, L., Shack, S., Stetler-Stevenson, W. G., Hudgins, W. R., and Samid, D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol., 103: 335-340, 1994.
7. Hudgins, W. R., Shack, S., Myers, C. E., and Samid, D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Biochem. Pharmacol., 50: 1273-1279, 1995.
8. Sabelli, H. C., Fawcett, J., Gusovky, F., Javaid, J., Edwards, J., and Jeffriess, H. Urinary phenyl acetate: a diagnostic test for depression? Science (Washington DC), 220: 1187-1188, 1983.
9. Knowles, R. G., Clarkson, N. A., Pogson, C. I., Salter, M., Duch, D. S., and Edelstein, M. P. The role of tryptophan and kynurenine transport in the catabolism of tryptophan through indoleamine 2,3-dioxygenase. Adv. Exp. Med. Biol., 294: 161-166, 1991.
10. Taylor, M. W., and Feng, G. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan metabolism. FASEB J., 5: 2516-2522, 1991.
11. Lovastatin Study Group. Lovastatin 5-year safety and efficacy study. Arch. Intern. Med., 153: 1079-1087, 1993.
12. Sumi, S., Beauchamp, R. D., Townsend, C. M. J., Tatsuo, U., Murakami, M., Rajaraman, S., Ishizuka, J., and Thompson, J. C. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastro-enterology, 103: 982-989, 1992.
13. Jones, K. D., Couldwell, W. T., Hinton, D. R., Su, Y., He, S., Anker, L., and Law, R. E. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem. Biophys. Res. Commun., 205: 1681-1687, 1994.
14. Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., Trepel, J., Liang, B., Patronas, N., Venzon, D. J., Reed, E., and Myers, C. E. Phase I study of lovastatin, and inhibitor of the mevalonate pathway, in patients with cancer. Cancer Res., 2: 483-491, 1996.
15. Samid, D., Ram, Z., Hudgins, R., Shack, S., Liu, L., Walbridge, S., Oldffeld, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
16. Neish, W. J. P. Phenylacetic acid as a potential therapeutic agent for the treatment of human cancer. Experientia, 27; 860-861, 1971.
17. ras isoprenylation and phenotypic reversion. Int. J. Cancer, 63: 124-129, 1995.